1. Home
  2. |Insights
  3. |PODCAST: President Trump’s Energy Independence Executive Order – What Changes Can Companies Expect, and When? — C&M's First 100 Days Series

PODCAST: President Trump’s Energy Independence Executive Order – What Changes Can Companies Expect, and When? — C&M's First 100 Days Series

Client Alert | 1 min read | 04.06.17

As part of our First 100 Days series, Tom Lorenzen and Dan Leff, both part of Crowell & Moring’s Environment & Natural Resources Group, sit down to discuss President Trump’s energy independence executive order. Tom is a partner in the group and the former assistant chief with the DOJ’s Environment & Natural Resources Division. Dan is an associate who focuses on litigation, permitting, and counseling under environmental statutes including the Clean Water Act, Clean Air Act, and Endangered Species Act.

Discussed in this 17 minute podcast

  • An overview of the energy independence executive order.
  • What effect this might have on the Clean Power Plan, the NSPS, and the endangerment finding.
  • How ongoing litigation will be affected.
  • What other changes companies might expect.

Click below to listen or access from one of these links:
PodBean | SoundCloud | iTunes

Contacts

Insights

Client Alert | 7 min read | 09.14.26

AI in Life Sciences: Ten Legal Considerations and Risks of AI Use in Drug Discovery and Development

Over the past several years, the biopharmaceutical industry has embraced artificial intelligence and machine learning (AI/ML) in near lockstep with the pace of AI/ML innovations. Today, industry leaders are using AI/ML to, among other things: discover and assess biological pathways, target chemical structures and sequences; design proteins; model pre-clinical and clinical trials; recruit and screen potential patient populations; evaluate clinical trial results and biomarker data; prepare regulatory filings; and manage supply chains. Deployment of new AI/ML models promises extraordinary advances in pharmaceutical development. However, as with any technological and scientific advances, the use of AI/ML also poses substantial legal risks that life sciences companies need to consider and proactively manage. ...

View All Insights